Pilot Projects and Trans-Network Activities Core

试点项目和跨网络活动核心

基本信息

  • 批准号:
    9446709
  • 负责人:
  • 金额:
    $ 25.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-30 至 2019-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract: Pilot Projects and Trans-Network Activities Core The goal of the Pilot Projects and Trans-Network Activities Core is to support the development of research projects using PDX models that will advance the mission of the PDTC and PDXNet. The core will help to foster collaborative, translational research using well-characterized PDX models that recapitulate human disease. Projects will expand the scope of translational research and increase the number of investigators committed to testing CTEP agents using PDX models for developing the preclinical justification needed for Phase I/II clinical trials. Requests for Application (RFA) for two awards of $50,000 dollars a year will be solicited. One within the PDTC and one that is open to non-PDXNet members. The goal of these projects will be to support the translational goals of the PDTC to advance translational research through the use of PDX models or, research methods to enhance experimental validation and reproducibility across PDTCs. Requests for Applications (RFA) for PDX based projects will be requested annually. All developmental research project applications will be reviewed by Pilot Research Program Advisory Committee consisting of scientists (representing basic and applied science) with expertise in solid tumor cancers, a biostatistician, a patient advocate, and ad hoc members, as necessary (special expertise, no conflict of interest). This committee will make recommendations to the PDTC Leadership Committee, which will make final funding decisions. Relevance The work proposed will lead to increased utilization of PDXs as models of human disease that can be used as the preclinical justification for testing CTEP agents in patient sub-populations based on biomarkers.
项目概要/摘要:试点项目和跨网络活动核心 试点项目和跨网络活动核心的目标是支持研究的发展 使用PDX模型的项目将推进PDTC和PDXNet的使命。核心将有助于培养 使用表征良好的PDX模型进行协作、转化研究,重现人类疾病。 项目将扩大转化研究的范围,增加致力于研究的研究人员的数量。 使用PDX模型测试CTEP药物,以开发I/II期临床试验所需的临床前依据 审判申请(RFA)的申请要求,每年将有两个50 000美元的奖项。分之一内 PDTC和一个对非PDXNet成员开放。这些项目的目标是支持 PDTC的翻译目标是通过使用PDX模型或研究来推进翻译研究 提高PDTC实验验证和重现性的方法。申请要求 (RFA)将每年申请一次基于PDX的项目。所有发展研究项目的申请, 由科学家组成的试点研究计划咨询委员会(代表基础和 应用科学),具有实体瘤癌症方面的专业知识,生物统计学家,患者倡导者和特设 委员会成员,必要时(特殊专长,无利益冲突)。该委员会将提出建议 PDTC领导委员会将做出最终的资金决定。 相关性 所提出的工作将导致PDX作为人类疾病模型的利用率增加, 基于生物标志物在患者亚群中检测CTEP药物的临床前依据。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John F. Dipersio其他文献

John F. Dipersio的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John F. Dipersio', 18)}}的其他基金

Project 6- Targeting AML using bispecific and antibody drug conjugates
项目 6 - 使用双特异性和抗体药物偶联物靶向 AML
  • 批准号:
    10615336
  • 财政年份:
    2021
  • 资助金额:
    $ 25.44万
  • 项目类别:
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
优化造血干细胞移植治疗血液恶性肿瘤
  • 批准号:
    10469493
  • 财政年份:
    2017
  • 资助金额:
    $ 25.44万
  • 项目类别:
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
优化造血干细胞移植治疗血液恶性肿瘤
  • 批准号:
    10001462
  • 财政年份:
    2017
  • 资助金额:
    $ 25.44万
  • 项目类别:
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
优化造血干细胞移植治疗血液恶性肿瘤
  • 批准号:
    10596338
  • 财政年份:
    2017
  • 资助金额:
    $ 25.44万
  • 项目类别:
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
优化造血干细胞移植治疗血液恶性肿瘤
  • 批准号:
    9765193
  • 财政年份:
    2017
  • 资助金额:
    $ 25.44万
  • 项目类别:
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
优化造血干细胞移植治疗血液恶性肿瘤
  • 批准号:
    10738323
  • 财政年份:
    2017
  • 资助金额:
    $ 25.44万
  • 项目类别:
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
优化造血干细胞移植治疗血液恶性肿瘤
  • 批准号:
    10246817
  • 财政年份:
    2017
  • 资助金额:
    $ 25.44万
  • 项目类别:
RETARGETING AGENTS TO TREAT AML
重新定位药物治疗 AML
  • 批准号:
    9061646
  • 财政年份:
    2015
  • 资助金额:
    $ 25.44万
  • 项目类别:
RETARGETING AGENTS TO TREAT AML
重新定位药物治疗 AML
  • 批准号:
    9267349
  • 财政年份:
    2015
  • 资助金额:
    $ 25.44万
  • 项目类别:
RETARGETING AGENTS TO TREAT AML
重新定位药物治疗 AML
  • 批准号:
    8864581
  • 财政年份:
    2015
  • 资助金额:
    $ 25.44万
  • 项目类别:

相似海外基金

Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
  • 批准号:
    10760051
  • 财政年份:
    2023
  • 资助金额:
    $ 25.44万
  • 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
  • 批准号:
    2303692
  • 财政年份:
    2023
  • 资助金额:
    $ 25.44万
  • 项目类别:
    Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
  • 批准号:
    468168
  • 财政年份:
    2022
  • 资助金额:
    $ 25.44万
  • 项目类别:
    Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10427960
  • 财政年份:
    2022
  • 资助金额:
    $ 25.44万
  • 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
  • 批准号:
    10577074
  • 财政年份:
    2022
  • 资助金额:
    $ 25.44万
  • 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
  • 批准号:
    486588
  • 财政年份:
    2022
  • 资助金额:
    $ 25.44万
  • 项目类别:
    Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
  • 批准号:
    2760091
  • 财政年份:
    2022
  • 资助金额:
    $ 25.44万
  • 项目类别:
    Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10621188
  • 财政年份:
    2022
  • 资助金额:
    $ 25.44万
  • 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
  • 批准号:
    10891016
  • 财政年份:
    2021
  • 资助金额:
    $ 25.44万
  • 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
  • 批准号:
    10230365
  • 财政年份:
    2020
  • 资助金额:
    $ 25.44万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了